Lion Biotechnologies (NASDAQ: IOVA) and Digiliti Money (OTCMKTS:DGLT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Earnings and Valuation

This table compares Lion Biotechnologies and Digiliti Money’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Lion Biotechnologies N/A N/A -$52.89 million ($1.30) -6.77
Digiliti Money $7.97 million 0.24 -$15.16 million ($6.05) -0.03

Digiliti Money has higher revenue and earnings than Lion Biotechnologies. Lion Biotechnologies is trading at a lower price-to-earnings ratio than Digiliti Money, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Lion Biotechnologies and Digiliti Money’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lion Biotechnologies N/A -53.59% -51.25%
Digiliti Money -147.73% N/A -199.21%

Volatility & Risk

Lion Biotechnologies has a beta of 4.59, indicating that its share price is 359% more volatile than the S&P 500. Comparatively, Digiliti Money has a beta of -1.62, indicating that its share price is 262% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Lion Biotechnologies and Digiliti Money, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lion Biotechnologies 0 0 10 0 3.00
Digiliti Money 0 0 1 0 3.00

Lion Biotechnologies currently has a consensus target price of $15.31, suggesting a potential upside of 74.01%. Digiliti Money has a consensus target price of $6.00, suggesting a potential upside of 3,057.89%. Given Digiliti Money’s higher probable upside, analysts plainly believe Digiliti Money is more favorable than Lion Biotechnologies.

Insider and Institutional Ownership

75.9% of Lion Biotechnologies shares are owned by institutional investors. Comparatively, 11.3% of Digiliti Money shares are owned by institutional investors. 13.2% of Lion Biotechnologies shares are owned by insiders. Comparatively, 50.9% of Digiliti Money shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Lion Biotechnologies beats Digiliti Money on 6 of the 11 factors compared between the two stocks.

About Lion Biotechnologies

Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.

About Digiliti Money

Digiliti Money Group, Inc., formerly Digiliti Money, Inc., is a technology solutions and services provider to the financial services industry. The Company’s solutions and services enable its clients, such as banks, credit unions and alternative financial services providers (AFS) to offer their customers remote deposit capture (RDC) and prepaid mobile money technologies and related services. It offers RDC products for businesses and consumers; mobile money management products for consumers, and training and support services for its financial services industry customers. The RDC products are offered to banks and credit unions in the United States, Canada and Latin America. Its mobile money management products are offered to traditional financial institutions (FIs), as well as AFS in the United States, Canada and Latin America. These FIs and AFS providers include banks, credit unions, prepaid card issuers, check cashers and payday lenders.

Receive News & Ratings for Lion Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lion Biotechnologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.